About mirikizumab
Interleukin-23 p19 monoclonal antibody
Used for
- Treats moderately to severely active ulcerative colitis in adults.
- Treats moderately to severely active Crohn’s disease in adults.
Usual adult dose
Ulcerative colitis: induction is intravenous; maintenance is 200 mg under the skin every 4 weeks. Crohn’s disease dosing begins with intravenous induction, then maintenance under the skin every 4 weeks.
Common side effects
- Upper respiratory infections
- Injection-site reactions
- Joint pain
- Headache
Important warnings
- Serious infections can occur; treatment may be delayed during active infection.
- Screen for tuberculosis before treatment.
- Avoid live vaccines during treatment.
- Rarely, serious liver injury can occur; liver tests may be monitored.
Pregnancy
Human pregnancy data are limited. Use only when potential benefits justify possible risks; discuss treatment planning with a clinician.
Breastfeeding
It is unknown whether mirikizumab passes into breast milk. Consider benefits of breastfeeding and treatment when deciding.
Interactions
- Avoid live vaccines during treatment.
- Tell clinicians about all medicines and vaccines; no major drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.